TMCnet News SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast [December 11, 2020] SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast â Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment â â Statistically Significant Difference of Duration of Immune Response of NPS vs. Control: p=0.000094 - Â Â â Data to be Presented Today at the San Antonio Breast Cancer Symposium - NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (âSELLASâ or the âCompanyâ), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, announced today final data with up to 6 months follow-up from a Phase 2 randomized trial (the VADIS study) of the Companyâs nelipepimut-S (NPS) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in women with ductal carcinoma in situ (DCIS) of the breast who are HLA-A2+ or A3+ positive, express HER2 at IHC 1+, 2+, or 3+ levels, and are pre- or post-menopausal. This investigator-sponsored trial randomized patients to receive, prior to surgery, either GM-CSF followed by NPS two weeks later or GM-CSF alone.